<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36946">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068521</url>
  </required_header>
  <id_info>
    <org_study_id>13VR3</org_study_id>
    <nct_id>NCT02068521</nct_id>
  </id_info>
  <brief_title>Versartis Long-Term Extension Study of VRS-317</brief_title>
  <official_title>An Open-Label, Long-Term Extension Study of the Safety and Efficacy of A Long-acting Human Growth Hormone (VRS-317) in Children With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versartis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versartis Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol 13VR3 is designed as an open-label extension study assessing long-term VRS-317
      administration. It is open to subjects completing a Versartis Phase 2 or 3 study in children
      with growth hormone deficiency.

      Patients will be monitored for safety throughout their participation in the study. Safety
      will be monitored by physical examination, inspection of injection sites, vital signs and
      clinical laboratory determinations. Adverse events (AEs) and concomitant medications will be
      captured. AEs will be coded using CTCAE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Quarterly visits for up to 4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will have quarterly (every 3 months) in clinic visits throughout the study for up to 4 years. Safety assessments include recording of adverse events and concomitant medications, monitoring of injection sites, vital signs and clinical laboratory determinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual Height Velocity</measure>
    <time_frame>Annual assessments for up to 4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy will be assessed by annual height velocity (cm/yr) in the first year of cumulative treatment (first 12 months) and at each subsequent 12 month interval for up to 4 years.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics and pharmacodynamics (PK/PD)</measure>
    <time_frame>Day 1, Month 3, 6 and 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PK/PD peak and trough measurements will be assessed throughout the study with assessment of plasma VRS-317 concentrations and IGF-I and its binding proteins measured at pre-specified time points.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Pediatric Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Once Weekly VRS-317 Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive long-term repeat dosing of subcutaneous VRS-317 once per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semi-Monthly VRS-317 Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive long-term repeat dosing of subcutaneous VRS-317 twice per month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Once Monthly VRS-317 Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive long-term repeat dosing of subcutaneous VRS-317 once per month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VRS-317</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Once Weekly VRS-317 Administration</arm_group_label>
    <arm_group_label>Semi-Monthly VRS-317 Administration</arm_group_label>
    <arm_group_label>Once Monthly VRS-317 Administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of a Versartis Phase 2 or Phase 3 clinical study in pediatric patients
             with GHD

          -  Willing and able to comply with all study procedures

        Exclusion Criteria:

          -  Withdrawal from a Versartis clinical study in pediatric patients with GHD

          -  Lack of compliance in a Versartis clinical study in pediatric patients with GHD

          -  Use of prohibited medications that may alter responses to the test product

          -  Presence of certain medical condition conditions if condition or treatment of
             condition may alter response to test product
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Bright, MD</last_name>
    <role>Study Director</role>
    <affiliation>Versartis Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Humphriss, MBA</last_name>
    <phone>650-963-8587</phone>
    <email>ehumphriss@versartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George Bright, MD</last_name>
    <phone>650-963-8589</phone>
    <email>gbright@versartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://versartis.com</url>
    <description>Versartis website</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth Hormone Deficiency</keyword>
  <keyword>Pediatric Growth Hormone Deficiency</keyword>
  <keyword>GHD</keyword>
  <keyword>PGHD</keyword>
  <keyword>VRS-317</keyword>
  <keyword>Versartis</keyword>
  <keyword>Growth disorder</keyword>
  <keyword>Long acting growth hormone</keyword>
  <keyword>Growth hormone</keyword>
  <keyword>Weekly growth hormone dosing</keyword>
  <keyword>Semi-monthly growth hormone dosing</keyword>
  <keyword>Monthly growth hormone dosing</keyword>
  <keyword>IGF-I</keyword>
  <keyword>Short stature</keyword>
  <keyword>Height velocity</keyword>
  <keyword>Annual height velocity</keyword>
  <keyword>Growth rate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
